BIOLASE, Inc. Annual report pursuant to Section 13 and 15(d)

Annual report pursuant to Section 13 and 15(d)

Consolidated Statements Of Redeemable Preferred Stock And Shareholders' Equity

Consolidated Statements Of Redeemable Preferred Stock And Shareholders' Equity - USD ($) $ in Thousands	Total	Series E Convertible Preferred Stock	June 2020 Warrants	July 2020 Warrants	Series F Preferred Stock	Convertible Preferred Stock	Convertible Preferred Stock Series E Convertible Preferred Stock	Convertible Preferred Stock Series F Preferred Stock	Additional Paid-in Capital	Additional Paid-in Capital Series E Convertible Preferred Stock	Additional Paid-in Capital June 2020 Warrants	Additional Paid-in Capital July 2020 Warrants	Additional Paid-in Capital Series F Preferred Stock	Convertible Preferred Stock	Convertible Preferred Stock Series F Preferred Stock	Accumulated Other Comprehensive Loss	Accumulated Deficit	Mezzanine Equity Series E Convertible Preferred Stock
Balance at Dec. 31, 2017	$ 29,260					$ 20			$ 224,992							$ (576)	$ (195,176)
Balance, shares at Dec. 31, 2017						20,468,000
Exercise of stock options, net	$ 2								2
Exercise of stock options, net, shares	1,000					1,000
Fees for rights offering	$ (38)								(38)
Stock-based compensation	2,627								2,627
Issuance of stock from RSUs, net	1					$ 1
Issuance of stock from RSUs, net, share						603,000
Warrant issued in connection with debt instruments	847								847
Net loss	(21,516)																(21,516)
Foreign currency translation adjustment	(94)															(94)
Balance at Dec. 31, 2018	11,089					$ 21			228,430							(670)	(216,692)
Balance (in shares) at Dec. 31, 2018						21,072,000
Issuance of Convertible Preferred Stock, net of issuance costs																		$ 3,965
Issuance of Convertible Preferred Stock, net of issuance costs, shares																		70,000
Sale of common stock	4,250					$ 9			4,241
Sale of common stock, shares						8,993,000
Exercise of stock options, net	$ 4								4
Exercise of stock options, net, shares	2,000					2,000
Stock-based compensation	$ 2,395								2,395
Issuance of stock from RSUs, net	364					$ 1			363
Issuance of stock from RSUs, net, share						1,372,000
Warrant issued in connection with debt instruments	161								161
Net loss	(17,855)																(17,855)
Foreign currency translation adjustment	(31)															(31)
Balance at Dec. 31, 2019	$ 3,965
Balance, shares at Dec. 31, 2019	70,000	69,565																70,000
Balance at Dec. 31, 2019	$ 377					$ 31			235,594							(701)	(234,547)	$ 3,965
Balance (in shares) at Dec. 31, 2019	31,439,000					31,439,000
Conversion of convertible preferred stock		$ 3,965					$ 7	$ 43		$ 3,958			$ 16,928		$ (16,971)			$ (3,965)
Conversion of convertible preferred stock, shares							6,957,000	42,795,000							(17,000)			(70,000)
Sale of common stock	$ 3,798					$ 11			3,787
Sale of common stock, shares						10,800,000
Sale of common stock warrants			$ 3,031	$ 9,450							$ 3,031	$ 9,450
Stock offering costs	(856)								(856)
Stock-based compensation	2,591								2,591
Issuance of stock from RSUs, net	163					$ 2			161
Issuance of stock from RSUs, net, share						1,856,000
Warrant issued in connection with debt instruments	67								67
Issuance of convertible preferred stock in rights offering, net of offering costs					$ 2,411										$ 2,411
Issuance of convertible preferred stock in rights offering, net of offering costs, shares															18,000
Beneficial conversion on Convertible Preferred Stock													2,700		$ (2,700)
Deemed dividend on convertible preferred stock	17,378												$ (17,378)		$ 17,378
Exercise of common stock warrants	1,544					$ 4			1,540
Common stock warrants exercised, shares						3,862,000
Net loss	(16,829)																(16,829)
Foreign currency translation adjustment	$ 316															316
Balance, shares at Dec. 31, 2020	0	0												1,000
Balance at Dec. 31, 2020	$ 10,028					$ 98			$ 261,573					$ 118		$ (385)	$ (251,376)
Balance (in shares) at Dec. 31, 2020	97,708,502					97,709,000